ENGELBERG CENTER for
Health Care Reform
at BROOKINGS

Accelerating Drug Development for Sickle Cell Disease

Washington Plaza Hotel • Washington, DC
Thursday, October 9, 2014

9:00 a.m.	**Welcome, Overview, and Meeting Objectives** Mark McClellan, Engelberg Center for Health Care Reform Gregory Daniel, Engelberg Center for Health Care Reform
9:15 a.m.	**Opening Remarks** Ann Farrell, US Food and Drug Administration
9:30 a.m.	**Facilitating Drug Development for Sickle Cell Disease** Nicole Verdun, US Food and Drug Administration
9:45 a.m.	**Session I: Clinical Trial Endpoint Selection: Drug development for Chronic Prevention versus Acute Management** Mark McClellan, Moderator
	Opening presentation: Wally R. Smith, Virginia Commonwealth University
11:00 a.m.	**Break**
11:15 a.m.	**Session II: Special Considerations for Adult Clinical Trials** Gregory Daniel, Moderator
	Opening presentation: Ken Ataga, University of North Carolina-Chapel Hill
12:15 p.m.	**Lunch**
1:15 p.m.	**Session III: Special Considerations for Pediatric Clinical Trials** Mark McClellan, Moderator
	Opening presentation: Carlton Dampier, Emory University
2:15 p.m.	**Session IV: Development of Patient Reported Outcomes** Mark McClellan, Moderator
	Opening presentation: Carlton Haywood, Johns Hopkins University
3:00 p.m.	**Break**
3:15 p.m.	**Session V: Identifying Next Steps**
3:45 p.m.	**FDA Wrap-Up of Today's Discussion** Kathy Robie-Suh, US Food and Drug Administration

ENGELBERG CENTER for
Health Care Reform
at BROOKINGS

4:00 p.m. **Closing Remarks**
Mark McClellan

4:15 p.m. **Adjournment**

Convened by the Engelberg Center for Health Care Reform at Brookings and supported by a cooperative agreement with the U.S. Food and Drug Administration.